Tags Archive Navigation
icon
-
Media ReleaseNew extension study data with Novartis drug Gilenya shows patients successfully treated for up to 7 years in relapsing MS
-
Media ReleaseNovartis announces update to United States prescribing information for MS therapy Gilenya following FDA review
-
Media ReleaseNovartis expands transplant portfolio with Hecoria®, the first generic tacrolimus that can be prescribed by brand name
-
Media ReleaseNovartis launches Arcapta™ Neohaler™, a novel once-daily bronchodilator for chronic obstructive pulmonary disease
-
Media ReleasePlaintiff Sales Representatives and Novartis Pharmaceuticals Corporation Resolve Class Action Wage and Hour Claims
-
Media ReleaseNovartis Pivotal Study of Exjade® Shows Significant Reduction of Iron Overload in Patients with Non-transfusion-dependent Thalassemia
-
Media ReleaseTwo Novartis Phase III Studies Show Twice as Many Ph+ CML Patients Achieve Deeper Levels of Response With Tasigna® Compared to Gleevec®
-
Media ReleaseNovartis Phase III Study Shows ACZ885 Helped Substantially Reduce Steroid Use in 45% of Patients With Serious Form of Childhood Arthritis
-
Media ReleaseNovartis Drug Afinitor® Helps Women With Advanced Breast Cancer Live Significantly Longer Without Their Disease Progressing
-
Media ReleaseNovartis Study Shows QTI571 Significantly Improved Walking Distance in Patients with Life-Threatening Pulmonary Arterial Hypertension
-
Media ReleaseNovartis Drug Afinitor® Effective in Patients With Non-Cancerous Kidney Tumors Associated With TSC in Phase III Trial
-
Media ReleaseNovartis Study Showed ACZ885 Provided Substantial Symptom Relief in 84% of Patients With the Most Serious Form of Childhood Arthritis
Pagination
- ‹ Previous page
- 1
- …
- 22
- 23
- 24
- 25
- 26
- 27
- 28
- …
- 50
- › Next page